The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Redefining high-risk myeloma in the context of upfront quadruplet therapy and ASCT
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses redefining functional high-risk multiple myeloma, proposing that disease progression within 36 months should serve as the new benchmark in the era of upfront quadruplet therapy and autologous stem cell transplantation (ASCT). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
